ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-OR101

Unbiased Proteomics Distinguishes Chronic and Acute Antibody-Mediated Rejection in Donor-Specific Antibody-Positive Kidney Transplant Recipients

Session Information

Category: Transplantation

  • 2101 Transplantation: Basic

Authors

  • Manion, Kieran, Toronto General Research Institute, Toronto, Ontario, Canada
  • Allen, Maya A., Toronto General Research Institute, Toronto, Ontario, Canada
  • Clotet Freixas, Sergi, McMaster University, Hamilton, Ontario, Canada
  • John, Rohan, University Health Network, Toronto, Ontario, Canada
  • Konvalinka, Ana, Toronto General Research Institute, Toronto, Ontario, Canada
Background

Nearly a million North Americans have end-stage renal disease, for which transplantation of a new kidney is the best treatment; however, >50% of grafts fail by 10 years due mainly to antibody-mediated rejection (ABMR), where recipient donor-specific antibodies (DSA) can drive tissue injury. Unfortunately, presence of DSA alone cannot predict ABMR, as 30-60% of DSA+ patients do not develop rejection. We aim to identify factors regulating kidney protein expression in DSA+ kidney transplant recipients with and without ABMR.

Methods

Kidney biopsies were obtained from DSA+ kidney transplant recipients with no rejection (NR; n=45) or ABMR (acute, n=25; chronic, n=25; mixed ABMR/cellular rejection, n=25). Glomeruli (glom) and tubulointerstitium (TI) extracted from kidney biopsies using laser capture microdissection were digested to peptides and analyzed by liquid chromatography mass spectrometry. MaxQuant and Perseus software were used for protein identification and differential expression. Differentially expressed proteins (ANOVA, p<0.05) were mapped to signaling pathways using pathDIP (FDR: BH, q<0.05).

Results

180 glomerular and 325 tubulointerstitial proteins were significantly differentially expressed between DSA+ patients with NR or with a subtype of ABMR (Fig 1). Proteins upregulated in acute or mixed ABMR mapped significantly to pathways for MHC and interferon (IFN) signaling in TI (MHC pathway, q=5.5e-12; IFN signaling, q=3.3e-8). In contrast, proteins upregulated in chronic ABMR mapped to the complement cascade (glom, q=2.9e-3; TI, q=6.8e-11) and extracellular matrix organization (glom, q=2.1e-7; TI, q=2.5e-4) in both compartments. DSA+ patients with any ABMR subtype showed significant downregulation of proteins linked to pyruvate metabolism in both compartments compared to NR (glom, q=2.7e-4; TI, q=6.9e-14).

Conclusion

Our results suggest that while both acute and chronic ABMR in DSA+ kidney transplant patients involve altered metabolism, distinct immune-mediated mechanisms may drive tissue damage in the individual subtypes.

Funding

  • Government Support – Non-U.S.